Schedule 13D/A Filing by Lindsay A. Rosenwald, M.D. for Fortress Biotech, Inc.

Lindsay A. Rosenwald, M.D. is filing Amendment No. 5 to Schedule 13D concerning the Common Stock of Fortress Biotech, Inc. The filing reports beneficial ownership of 6,917,715 shares of Common Stock, representing approximately 20.7% of the outstanding shares. This ownership includes directly held shares, unvested restricted stock, shares underlying exercisable warrants, and shares held by Paramount Biosciences, LLC and Capretti Grandi LLC, over which Dr. Rosenwald has voting and dispositive control. The filing details shares granted on January 1, 2025, and March 18, 2026, under the company's Long Term Incentive Plan, which are subject to repurchase by the Issuer until vested. Dr. Rosenwald has sole voting and dispositive power over the reported shares. The filing states that Dr. Rosenwald has no present plans for significant corporate transactions, changes in management or capitalization, or other actions that would impede control of the Issuer. Shares held in trusts for family members, over which Dr. Rosenwald lacks control, are excluded from the reported total. The filing is an amendment to a previous filing dated January 28, 2016.